Company & Sponsor Intelligence

Shire

Evidence-linked intelligence derived from the current NeuroRisk clinical research corpus. Coverage reflects indexed source data and is not a claim of complete company activity.

Request enterprise analysis →

Indexed trials15

Recruiting0

Completed14

Countries2

Therapeutic footprint

adhddepressioneating_disorders

Indexed studies

NCT01010750Lisdexamfetamine Dimesylate (LDX) Pilot Cognition Study to Evaluate the Utility of a Standardized Battery of Tests in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE1

NCT00557960ADDERALL XR (Mixed Salts of a Single-entity Amphetamine) and STRATTERA ( Atomoxetine Hydrochloride) Compared to Placebo on Simulated Driving Safety and Performance and Cognitive Functioning in Adults With ADHD
adhd · United StatesPHASE3

NCT04866043Drug Use Study With VYVANSE® in Australia for Binge Eating Disorder
eating_disorders · AustraliaCOMPLETED

NCT00151996Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)
adhd · PHASE2

NCT03325881Efficacy and Safety of SHP465 at 6.25 mg in the Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in Children Aged 6-12 Years
adhd · United StatesPHASE3

NCT00734578Efficacy and Safety of SPD503 in Combination With Psychostimulants
adhd · United StatesPHASE3

NCT00764868Vyvanse Adolescent Open-Label Safety and Efficacy Extension Study
adhd · United StatesPHASE3

NCT00697515Safety and Efficacy Workplace Environment Study of Lisdexamfetamine Dimesylate (LDX) in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
adhd · United StatesPHASE3

NCT00928148The Safety and Efficacy of SPD465 in Adults With Attention Deficit Hyperactivity Disorder (ADHD)
adhd · PHASE2

NCT00784654Double-blind, Placebo-controlled, Randomised Withdrawal, Extension, Safety and Efficacy Study of LDX in Children and Adolescents Aged 6-17
adhd · United StatesPHASE3

NCT01435759SPD489 in Combination With an Antidepressant in the Treatment of Adults With Major Depressive Disorder
depression · United StatesPHASE2

NCT00152022Efficacy and Safety of SPD465 in Adults With Moderately Symptomatic ADHD.
adhd · PHASE3

Intelligence layer updated: 2026-10-14 06:11:28.884102+00:00

Enterprise intelligence

Compare sponsor activity, recruiting momentum, therapeutic exposure, geography and connected research signals across the neuroscience ecosystem.

Request comparative intelligence →